ABIO ARCA biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABIO

Price (delayed)

$2.14

Market cap

$30.84M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.69

Enterprise value

-$11.33M

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically ...

Highlights
The company's quick ratio has surged by 146% YoY and by 65% QoQ
ARCA biopharma's EPS has soared by 50% YoY and by 32% from the previous quarter
The company's equity fell by 18% YoY and by 2.5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.arcabiopharma.com
Peers: CYTK PTN MDT UTHR

Key stats

What are the main financial stats of ABIO
Market
Shares outstanding
14.41M
Market cap
$30.84M
Enterprise value
-$11.33M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$9.93M
EBITDA
-$9.81M
Free cash flow
-$10.91M
Per share
EPS
-$0.69
Free cash flow per share
-$0.76
Book value per share
$2.89
Revenue per share
$0
TBVPS
$2.99
Balance sheet
Total assets
$43.09M
Total liabilities
$1.41M
Debt
$280,000
Equity
$41.67M
Working capital
$41.57M
Liquidity
Debt to equity
0.01
Current ratio
37.72
Quick ratio
37.5
Net debt/EBITDA
4.3
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-21.2%
Return on equity
-22.4%
Return on invested capital
N/A
Return on capital employed
-23.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABIO stock price

How has the ARCA biopharma stock price performed over time
Intraday
0.47%
1 week
-1.83%
1 month
0.94%
1 year
-8.94%
YTD
-9.7%
QTD
-9.7%

Financial performance

How have ARCA biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.6M
Net income
-$9.93M
Gross margin
N/A
Net margin
N/A
ARCA biopharma's net income has increased by 49% YoY and by 31% QoQ
ABIO's operating income is up by 45% year-on-year and by 28% since the previous quarter

Growth

What is ARCA biopharma's growth rate over time

Valuation

What is ARCA biopharma stock price valuation
P/E
N/A
P/B
0.74
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ARCA biopharma's EPS has soared by 50% YoY and by 32% from the previous quarter
The company's equity fell by 18% YoY and by 2.5% QoQ
ABIO's price to book (P/B) is 8% lower than its 5-year quarterly average of 0.8 and 8% lower than its last 4 quarters average of 0.8

Efficiency

How efficient is ARCA biopharma business performance
The return on equity has grown by 32% year-on-year and by 28% since the previous quarter
ARCA biopharma's return on assets has increased by 32% YoY and by 27% QoQ

Dividends

What is ABIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABIO.

Financial health

How did ARCA biopharma financials performed over time
The company's quick ratio has surged by 146% YoY and by 65% QoQ
The company's current ratio has surged by 142% YoY and by 64% QoQ
The company's debt is 99% lower than its equity
The company's debt fell by 27% YoY and by 7% QoQ
The company's equity fell by 18% YoY and by 2.5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.